BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26073389)

  • 1. Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials.
    McKenney J; Bays H; Gleim G; Mitchel Y; Kuznetsova O; Sapre A; Sirah W; Maccubbin D
    J Clin Lipidol; 2015; 9(3):313-25. PubMed ID: 26073389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
    Chen F; Maccubbin D; Yan L; Sirah W; Chen E; Sisk CM; Davidson M; Blomqvist P; McKenney JM
    Int J Cardiol; 2013 Jul; 167(1):225-31. PubMed ID: 22305632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
    HPS2-THRIVE Collaborative Group
    Eur Heart J; 2013 May; 34(17):1279-91. PubMed ID: 23444397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
    Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF
    Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
    Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients.
    Kush D; Hu DY; Ye P; Kim HS; Chen E; Sirah W; McCrary Sisk C; Paolini JF; Maccubbin D
    Cardiology; 2009; 114(3):192-8. PubMed ID: 19602880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of laropiprant on niacin-induced flushing.
    Maccubbin DL; Chen F; Anderson JW; Sirah W; McCrary Sisk C; Kher U; Olsson AG; Bays HE; Mitchel YB
    Am J Cardiol; 2012 Sep; 110(6):817-22. PubMed ID: 22683042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
    Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
    Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.
    Ballantyne C; Gleim G; Liu N; Sisk CM; Johnson-Levonas AO; Mitchel Y
    J Clin Lipidol; 2012; 6(3):235-43. PubMed ID: 22658147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia.
    Kush D; Kim HS; Hu DY; Liu J; Sirah W; Sapre A; McCrary Sisk C; Paolini JF; Maccubbin D
    J Clin Lipidol; 2009; 3(3):179-86. PubMed ID: 21291812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
    Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
    Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
    Haynes R; Valdes-Marquez E; Hopewell JC; Chen F; Li J; Parish S; Landray MJ; Armitage J; ; ;
    Clin Ther; 2019 Sep; 41(9):1767-1777. PubMed ID: 31447131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
    McKenney J; Bays H; Koren M; Ballantyne CM; Paolini JF; Mitchel Y; Betteridge A; Kuznetsova O; Sapre A; Sisk CM; Maccubbin D
    J Clin Lipidol; 2010; 4(2):105-112.e1. PubMed ID: 21122637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Shah S; Ceska R; Gil-Extremera B; Paolini JF; Giezek H; Vandormael K; Mao A; McCrary Sisk C; Maccubbin D
    Int J Clin Pract; 2010 May; 64(6):727-38. PubMed ID: 20518948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects.
    Lai E; Schwartz JI; Dallob A; Jumes P; Liu F; Kraft WK; Royalty J; Chodakewitz JA; McCrary Sisk C; Radziszewski W; Wagner JA
    Platelets; 2010; 21(3):191-8. PubMed ID: 20163197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
    Farnier M; Chen E; Johnson-Levonas AO; McCrary Sisk C; Mitchel YB
    Vasc Health Risk Manag; 2014; 10():279-90. PubMed ID: 24855368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
    Bays H; Shah A; Dong Q; McCrary Sisk C; Maccubbin D
    Int J Clin Pract; 2011 Apr; 65(4):436-45. PubMed ID: 21401833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.